Medicare coverage in 2026
The Medicare GLP-1 Bridge is live and runs through December 31, 2027. CMS furnishes Wegovy, Foundayo and the Zepbound KwikPen (not the single-dose vials or pens) for a flat $50 a month to Part D beneficiaries, for weight-management prescriptions only. You qualify with:
- BMI 35 or higher, or
- BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or CKD stage 3a or worse, or
- BMI 27 or higher with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
If you qualify, $50 a month beats every cash program on our chart. Check whether you qualify in four questions →
Medicare Part D coverage of GLP-1 in 2026 depends on which indication applies to you. For the full cost picture, the copay by indication and the cash floor if nothing applies, see the Medicare GLP-1 cost guide:
Without either indication: regular Part D does not cover a weight-loss-indication GLP-1. Since July 1, 2026, the Medicare GLP-1 Bridge covers it at $50 a month if you meet the clinical criteria above the grid. If you do not qualify for the Bridge either, the realistic options are cash-pay compounded (see cash-pay rankings) or patient assistance through NovoCare or LillyDirect (see every cost-reduction path).
If you have a SURMOUNT-OSA-qualifying sleep apnea diagnosis, that is a third Medicare-eligible pathway for Zepbound as of December 2024. We maintain a prior-authorization letter templates with the sleep-study documentation requirements and the trial citations. The CV indication templates and T2D templates are also live.
Federal retirees:if you carry FEHB alongside Medicare, your federal plan covers Wegovy and Zepbound with prior authorization, independent of Medicare’s obesity exclusion. FEHB Blue Cross coverage for Wegovy and Zepbound →
Military retirees: TRICARE For Life excludes weight-loss drugs, unlike FEHB. On TRICARE Prime or Select, Wegovy and Zepbound are covered for weight management with prior authorization. TRICARE GLP-1 coverage in full →
Sarcopenia, muscle loss and fall risk
Rapid weight loss in adults 65+ includes a meaningful share of lean mass. This compounds age-related sarcopenia and can increase fall risk if unaddressed. The article below covers the dose-adjustment, protein-intake, and resistance-training protocols obesity-medicine specialists use to protect muscle during GLP-1 treatment. Muscle sits alongside the other things rapid loss changes, and what weight loss does to skin and hair covers each with the evidence behind it.
Dose strategy for seniors
Most obesity-medicine specialists recommend a lower maintenance dose for adults 65+. Semaglutide 1.0-1.7 mg weekly often produces meaningful weight loss with substantially less appetite suppression and side-effect burden than the approved maximum of 2.4 mg. Tirzepatide 7.5-10 mg weekly is the comparable senior maintenance range vs the 15 mg approved maximum.
Slower titration also matters: every 6-8 weeks instead of every 4 weeks. This reduces GI side effects and allows polypharmacy interactions to be observed before reaching maintenance dose.
Patient-assistance pathways
For fixed-income retirees, the standard cash-pay path may not be affordable. Three pathways worth evaluating:
- NovoCare Wegovy ($149 pill starter, $349 injection) or LillyDirect Zepbound vials ($299-$449/mo)
- State-specific senior pharmaceutical assistance: New York EPIC, New Jersey PAAD/Senior Gold, Pennsylvania PACE/PACENET
- 340B clinic access if you live near an FQHC or safety-net hospital
If you live rural and don’t have broadband
All telehealth programs require email and basic web navigation. For rural senior patients without reliable broadband, two realistic options:
- Ask a family member to handle the intake for you.
- Ask your primary-care doctor to prescribe GLP-1 directly at your next in-person visit, with Medicare Part D coverage if the indication applies.
Telehealth is built for connected patients. In-person care remains the better path for the rural-senior population.
Top programs for senior patients
Three programs in our chart handle the polypharmacy and clinical-depth concerns common in senior care:
Cheapest cash routes this week
Frequently asked questions
Does Medicare cover Wegovy or Zepbound for weight loss?
Not under the regular Part D benefit: a 2003 statute excludes weight-loss drugs. Two indication-specific paths exist: Wegovy for established cardiovascular disease (since March 2024) and Zepbound for moderate-to-severe obstructive sleep apnea (since December 2024). Since July 1, 2026, and running through December 31, 2027, the Medicare GLP-1 Bridge has added a third path: a flat $50 a month for Wegovy, Foundayo or the Zepbound KwikPen for Part D beneficiaries who meet CMS clinical criteria (weight-management prescriptions only). The Bridge covers the KwikPen only, not the single-dose vials or pens.
What are the cash options for seniors without Medicare coverage?
The oral Wegovy pill runs $299 a month at maintenance doses through NovoCare ($149 at the starter dose) and branded Zepbound vials run $299 to $449 a month through LillyDirect. Cash-pay telehealth programs with compounded semaglutide start at $149 a month. State senior pharmaceutical assistance programs (New York EPIC, New Jersey PAAD, Pennsylvania PACE) can lower costs further. Prices checked every Monday.
Does GLP-1 cause muscle loss in older adults?
The DXA substudies in SURMOUNT-1 and STEP 1 found 25 to 40 percent of lost weight was lean mass, and the risk matters more after 65 because baseline muscle mass is lower. Specialists counter it with protein targets, resistance training, slower titration (every 6 to 8 weeks) and a lower maintenance dose: semaglutide 1.0 to 1.7 mg weekly or tirzepatide 7.5 to 10 mg weekly are the common senior maintenance ranges.
